
House Dust Mite Allergy Immunotherapy Tablet

Wiwanitkit V

Joseph Ayo Babalola University, Ikeji-Arakeji, Nigeria

Key words: House dust mite. Allergy. Immunotherapy. Tablet.

Palabras clave: Ácaro del polvo de casa. Alergia. Inmunoterapia. Tableta.

To the Editor:

A very interesting report was recently published on the orodispersible house dust mite allergy sublingual immunotherapy (HDM-SLIT) tablet in which Corzo et al [1] noted that “doses up to 12 development units of HDM SLIT-tablet were tolerated in the selected populations, and thus are suitable for further clinical investigations in adults and children with HDM respiratory allergic disease.” HDM allergy immunotherapy, however, is a major challenge in allergology. The HDM SLIT-tablet is a new drug that has proven useful in several allergic diseases as well as asthma [2,3]. Some authors, however, have offered a more measured opinion on the benefits of the tablet. Pham-Thi et al [4], for example, noted that SLIT with tablets of HDM extract “does not provide additional benefit, despite a significant reduction in allergic response to HDM.” In addition, because the HDM SLIT-tablet is relatively new, data on its short- and long-term adverse effects need to be closely monitored.

References

1. Corzo JL, Carrillo T, Pedemonte C, Plaza Martin AM, Martín Hurtado S, Dige E, Calderon MA. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. *J Investig Allergol Clin Immunol*. 2014;24:154-61.
2. de Blay F, Kuna P, Prieto L, Ginko T, Seitzberg D, Riis B, Canonica GW. SQ HDM SLIT-tablet (ALK) in treatment of asthma - Post hoc results from a randomised trial. *Respir Med*. 2014 Aug 7. pii: S0954-6111(14)00276-5. doi: 10.1016/j.rmed.2014.07.017. [Epub ahead of print]
3. Mosbech H, Deckelmann R, de Blay F, Pastorello EA, Trebas-Pietras E, Andres LP, Malcus I, Ljørring C, Canonica GW. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial. *J Allergy Clin Immunol*. 2014;134:568-575.e7.
4. Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. *Pediatr Allergy Immunol*. 2007;18:47-57

■ *Manuscript received September 8, 2014; accepted for publication, October 9, 2014.*

Viroj Wiwanitkit
Wiwanitkit House
Bangkhæ, Bangkok
Thailand 10160
E-mail: wviroj@yahoo.com